Haemonetics Corp. shares dropped in the extended session Monday after the company cut its outlook for the year. Haemonetics shares fell 12% to $29.29. The company, which specializes in blood-component collection and transfusion devices and services, cut its full-year forecast earnings range to $1.65 and $1.75 a share, from a previous range of $1.98 and $2.08 a share, on revenue of $910 million to $920 million. Analysts surveyed by FactSet had forecast $2.02 a share on revenue of $946.8 million.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News